What Are the Therapeutic Applications of TAK279?
Abstract TAK279 is a second-generation selectively covalent Bruton's tyrosine kinase (BTK) Inhibitor and has therapeutic application in different cancer types and relevant autoimmune disorders. TAK279 has a remarkable 70% overall response rate in patients with chronic lymphocytic leukemia (CLL), said to be better than the recognition of standard treatments having about a 40% reaction. Notably, …
What Are the Therapeutic Applications of TAK279? Read More »